About Sarah Cannon Research Institute at HealthONE
Sarah Cannon Research Institute at HealthONE offers the latest therapies through clinical trials to patients in our community. Through Sarah Cannon, we are a part of a network that has conducted community-based clinical trials for more than 20 years and 600+ first-in-man clinical trials to date. Sarah Cannon Research Institute has been a clinical trial leader in most approved cancer therapies over the last 10 years. The Sarah Cannon Research Institute at HealthONE Drug Development Unit (DDU) offers oncology clinical trials at the earliest phases of research and was designed to meet the specialized needs of patients seeking advanced cancer treatment options.
Our Integrated Care
Together, Sarah Cannon Research Institute and HealthONE offer integrated cancer services and treatment options to patients across the Rocky Mountain region. Through our partnership, we pair cutting-edge clinical cancer research with state-of-the-art technology to enhance the lives of cancer patients.
Our Philosophy
Participation in a clinical trial is the first step in fighting cancer, not the last.®
At Sarah Cannon Research Institute at HealthONE, we believe clinical trials are a source of inspiration and a catalyst for hope. Our experienced team is committed to delivering the highest quality care, personalized attention and revolutionary technology to provide patients with access to promising and innovative clinical trials in Denver. Want to learn more about HealthONE’s partnership with Sarah Cannon? Find out more below.
Clinicians
- Gerald S. Falchook, MD – Director, Drug Development
- Michael L. Pearlman, MD, PhD -- Neuro-Oncology
- Manojkumar Bupathi, MD, PhD -- Genitourinary Oncology
- Jason Henry, MD -- Associate Director, DDU
- Ryan M. Weight, DO, MS -- Medical Oncology
Program Leaders
- Kelly Mozzetta — Senior Program Manager
- Yesenia Mastache — Clinic Manager
The First Step
Sarah Cannon Research Institute at HealthONE is determined to make a difference in the lives of our patients and so many others. We currently have clinical trials actively enrolling patients. If you are interested in finding out more information related to our clinical trials, please call: (720)-754-2610.
Speak to Your Doctor
If you are interested in participating in a clinical trial, contacting your doctor is the first step. We will coordinate with your doctor directly to see if you are a good fit for the trial. If you are eligible and choose to take part in a study, you may be able to receive new, cutting-edge treatment and help to improve the lives of future cancer patients.
What to Expect
- Experienced and personalized care from esteemed physicians and renowned leaders in cancer drug development
- Innovative cancer treatment options close to home in Denver
- Support from a passionate and caring team of medical professionals
- Clear and open communication about clinical trial options
- Personalized cancer treatment strategies through genomic tumor testing
- Our facility, located on the Presbyterian St. Luke’s Medical Center campus, includes a clinic, an infusion center, an investigational pharmacy, a lab processing area and office space.
Sarah Cannon Research Institute at HealthONE is part of Sarah Cannon, the Cancer Institute of HCA Healthcare. Together, Sarah Cannon and HealthONE offer integrated cancer services to communities across the greater Denver area and Rocky Mountain region, which can be accessed at the following HealthONE family of hospitals:
- The Medical Center of Aurora
- North Suburban Medical Center
- Presbyterian/St. Luke's Medical Center
- Rocky Mountain Blood and Marrow Transplant Program
- Rocky Mountain Hospital for Children
- Rose Medical Center
- Sky Ridge Medical Center
- Swedish Medical Center
Through our partnership, we pair cutting-edge research with world-class cancer services that span the entire cancer care journey from diagnosis through survivorship.
Open Trials and Patient Referrals
To view clinical cancer trials that are currently enrolling, click the link below. For more information about our current trials or for general inquiries, call us at (720)-754-2610.
Contact Us: (720)-754-2610Sarah Cannon Research Institute at HealthONE
1800 Williams Street
Suite 300
Denver, CO 80218
Open Clinical Trials
Phase 1/1b Dose Escalation/Expansion Study of NGM438 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumors
A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PYX‑ 106 in Subjects with Advanced Solid Tumors
An Open-Label, Multicenter, Phase 1 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti- Tumor Activity of RO7515629 in Participants with Unresectable and/or Metastatic HLA-G Positive Solid Tumors
Phase I/II First-in-Human Study of TT-10 as a Single Agent in Participants with Advanced Selected Solid Tumors
A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants with Advanced Solid Tumors
Phase 1/2 Open-label Trial of KVA12123 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
An open-label, phase 1, first-in-human, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics, and tumor response profile of the diacylglycerol kinase zeta inhibitor (DGKzi) BAY 2965501 in participants with advanced solid tumors
A Phase 1, First-in-Human, Dose-Finding and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb®808 in Combination with Pembrolizumab in Selected Advanced Solid Tumors
A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway
NCT05631327
Phase 1, Open-Label, Dose-Finding, and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of JZP341 in Adult Participants With Advanced or Metastatic Solid Tumors
A First-in-Human, Open-label, Dose Escalation and Expansion Study of Orally Administered JBI-802 in Patients with Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of AC176 in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) Who Have Progressed on at Least Two Prior Systemic Therapies
A Phase 1 Study of SGN-B7H4V in Advanced Solid Tumors
A Phase 1 Study to Assess BDTX-1535, an Oral EGFR Inhibitor, in Patients with Glioblastoma or Non-Small Cell Lung Cancer
A PHASE 1 DOSE ESCALATION AND EXPANDED COHORT STUDY OF P-MUC1C-ALLO1 IN ADULT SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT2527 in Patients with Advanced Solid Tumors
An Open-label, Dose Escalation and Expansion, Phase 1a/1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors
A PHASE 1A OPEN-LABEL, DOSE-ESCALATION, AND A PHASE 2 STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL ACTIVITY OF ST-067 ADMINISTERED SUBCUTANEOUSLY AS MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY SOLID TUMORS
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of AC682 in Patients with Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer
A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 as Monotherapy in Patients With Selected Advanced Solid Tumor
A Phase 1b open-label, multicenter dose escalation and expansion study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors (Pro00051409)
Phase 1 Open-label Study of SNX281 Given as Monotherapy and in Combination with a Checkpoint Inhibitor in Subjects with Advanced Solid Tumors and Lymphoma
A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Antitumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Anti-PD-1 in Patients with Metastatic Solid Tumors
A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-8263 in Adult Subjects with Advanced Solid Tumors
A Phase 1, First-in-Human, Open-Label, Dose-Escalation Study of IMGC936 (Anti-ADAM9 Antibody Drug Conjugate) in Patients with Advanced Solid Tumors
An Open-Label, Multicenter, Phase I Study of IGM-8444 as a Single Agent and in Combination with Chemotherapy-Based Regimens in Subjects with Relapsed and/or Refractory Solid Cancers
A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of PRT811 in Subjects with Relapsed/Refractory Myelofibrosis, Advanced Solid Tumors and Recurrent High-Grade Gliomas
A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects with Selected Advanced Solid Tumors (DUET-3)
A Multi-Center, Open Label Phase 1/2 Study Of CYT-0851, An Oral RAD51 Inhibitor, In Patients With Relapsed/Refractory B-Cell Malignancies And Advanced Solid Tumors
A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Adult Patients with Advanced Solid Tumors
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in Patients with Advanced Solid Tumors
A Phase 1 Dose-escalation Study of FF-10832 for the Treatment of Advanced Solid Tumors
A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With a Specific KRAS Mutation
A Phase 1, Multi-Center, Dose Escalation, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3068 in Adult Patients with Advanced Solid Tumors
A Phase 1 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors with Increased RET Activity
A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies
An Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 Single Agent in Patients with Metastatic Pancreatic Cancer or Metastatic Colorectal Cancer
A Phase 1/2a, open-label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of PEN-866 in patients with advanced solid malignancies
A Phase II Study to Evaluate the Activity of Commercially Available Molecularly Matched Targeted Therapies in Selected Tumor Types Based on Genomic Alterations
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
A Phase 1/2a, dose-escalation study of FF-10502-01 for the treatment of advanced solid tumors and lymphomas
A Multi-Center, Open-Label Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors
A Phase I, Open-Label,Multicentre Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD2811 in Patients with Advanced Solid Tumours
A Phase I Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 in Patients with Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein
Phase Ib Study Evaluating the c-Met Inhibitor INC280 in Combination With Bevacizumab in Glioblastoma Multiforme (GBM), Metastatic Colorectal Cancer (mCRC) and Metastatic Renal Cell Carcinoma (mRCC) Patients
Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
A Phase1/2 Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
NCT0416139
A phase 1/2 study of TPX-0046, a Novel Oral RET/SRC Inhibitor in Adult Subjects with Advanced/Mestatic Solid Tumors Harboring Oncogenic RET Fusions or Mutations.
Phase 1 study of FF-10850, topotecan liposome injection, in advanced solid tumors including ovarian and cervical carcinoma, sarcomas, and neuroendocrine tumors including small cell lung cancer
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1- Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NYESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
Phase I/II, Two-Part, Multicenter First-in-Human Study of DS-7300a in Subjects with Advanced Solid Malignant Tumors
A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Malignancies
A Phase 1 Dose Escalation and Expanded Cohort Study of P-PSMA-101 in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of ONCR-177, an Oncolytic Herpes Simplex Virus for Intratumoral Injection, Alone and in Combination with PD-1 Blockade in Adult Subjects with Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors
A Phase 1/1B First-in-Human Study of the SHP2 Inhibitor BBP-398 (formerly known as IACS-15509) in Patients with Advanced Solid Tumors
